Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
P Domingo, I Mur, GM Mateo, M del Mar Gutierrez… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
IL-6 receptor antagonist therapy for patients hospitalized for COVID-19: who, when, and how?
MA Matthay, AF Luetkemeyer - JAMA, 2021 - jamanetwork.com
(IL-6), based on the hypothesis that SARS-CoV-2 creates injury to the lung and other organs
in part through activation of cytokine and downstream proinflammatory networks. While …
in part through activation of cytokine and downstream proinflammatory networks. While …
Interleukin-6 receptor antagonists in critically ill patients with Covid-19
Remap-Cap Investigators - New England Journal of Medicine, 2021 - Mass Medical Soc
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
IL-6 inhibition in the treatment of COVID-19: a meta-analysis and meta-regression
E Tharmarajah, A Buazon, V Patel, JR Hannah… - Journal of Infection, 2021 - Elsevier
Summary Objectives Multiple RCTs of interleukin-6 (IL-6) inhibitors in COVID-19 have been
published, with conflicting conclusions. We performed a meta-analysis to assess the impact …
published, with conflicting conclusions. We performed a meta-analysis to assess the impact …
Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
This study investigated the efficacy and safety of interleukin-6 (IL-6) receptor antagonists
with standard care treatment in patients with coronavirus disease 2019 (COVID-19). The …
with standard care treatment in patients with coronavirus disease 2019 (COVID-19). The …
[HTML][HTML] Current evidence of interleukin-6 signaling inhibitors in patients with COVID-19: a systematic review and meta-analysis
Q Han, M Guo, Y Zheng, Y Zhang, Y De, C Xu… - Frontiers in …, 2020 - frontiersin.org
Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019
(COVID-19) because of its involvement in driving cytokine storm. This systematic review and …
(COVID-19) because of its involvement in driving cytokine storm. This systematic review and …
[HTML][HTML] Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
RT Pinzon, VO Wijaya, RB Buana - Journal of infection and public health, 2021 - Elsevier
Introduction Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …
Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
Remap-Cap Investigators, AC Gordon, PR Mouncey… - MedRxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu… - Jama, 2023 - jamanetwork.com
Importance The longer-term effects of therapies for the treatment of critically ill patients with
COVID-19 are unknown. Objective To determine the effect of multiple interventions for …
COVID-19 are unknown. Objective To determine the effect of multiple interventions for …
Decreased mortality in coronavirus disease 2019 patients treated with tocilizumab: a rapid systematic review and meta-analysis of observational studies
J Malgie, JW Schoones, BG Pijls - Clinical Infectious Diseases, 2021 - academic.oup.com
Background We systematically reviewed the literature to answer the following research
questions:(1) Does interleukin 6 (IL-6)(receptor) antagonist therapy reduce mortality in …
questions:(1) Does interleukin 6 (IL-6)(receptor) antagonist therapy reduce mortality in …
相关搜索
- meta analysis covid 19
- receptor antagonists covid 19
- meta analysis coronavirus disease
- meta analysis decreased mortality
- signaling inhibitors covid 19
- remap cap covid 19
- therapeutic agents covid 19
- coronavirus disease covid 19
- meta analysis signaling inhibitors
- meta analysis therapeutic agents
- meta regression covid 19